@article {671, title = {Autism Linked to Increased Oncogene Mutations but Decreased Cancer Rate.}, journal = {PLoS One}, volume = {11}, year = {2016}, month = {2016}, pages = {e0149041}, abstract = {

Autism spectrum disorder (ASD) is one phenotypic aspect of many monogenic, hereditary cancer syndromes. Pleiotropic effects of cancer genes on the autism phenotype could lead to repurposing of oncology medications to treat this increasingly prevalent neurodevelopmental condition for which there is currently no treatment. To explore this hypothesis we sought to discover whether autistic patients more often have rare coding, single-nucleotide variants within tumor suppressor and oncogenes and whether autistic patients are more often diagnosed with neoplasms. Exome-sequencing data from the ARRA Autism Sequencing Collaboration was compared to that of a control cohort from the Exome Variant Server database revealing that rare, coding variants within oncogenes were enriched for in the ARRA ASD cohort (p<1.0 x 10(-8)). In contrast, variants were not significantly enriched in tumor suppressor genes. Phenotypically, children and adults with ASD exhibited a protective effect against cancer, with a frequency of 1.3\% vs. 3.9\% (p<0.001), but the protective effect decreased with age. The odds ratio of neoplasm for those with ASD relative to controls was 0.06 (95\% CI: 0.02, 0.19; p<0.0001) in the 0 to 14 age group; 0.35 (95\% CI: 0.14, 0.87; p = 0.024) in the 15 to 29 age group; 0.41 (95\% CI: 0.15, 1.17; p = 0.095) in the 30 to 54 age group; and 0.49 (95\% CI: 0.14, 1.74; p = 0.267) in those 55 and older. Both males and females demonstrated the protective effect. These findings suggest that defects in cellular proliferation, and potentially senescence, might influence both autism and neoplasm, and already approved drugs targeting oncogenic pathways might also have therapeutic value for treating autism.

}, keywords = {Adolescent, Adult, Autism Spectrum Disorder, Child, Child, Preschool, Female, Genes, Tumor Suppressor, Genetic Predisposition to Disease, Humans, Infant, Male, Middle Aged, Mutation, Neoplasms, Oncogenes, Prevalence, Young Adult}, issn = {1932-6203}, doi = {10.1371/journal.pone.0149041}, author = {Darbro, Benjamin W and Singh, Rohini and Zimmerman, M Bridget and Mahajan, Vinit B and Bassuk, Alexander G} } @article {647, title = {Management of Pediatric Aphakic Glaucoma With Vitrectomy and Tube Shunts.}, journal = {J Pediatr Ophthalmol Strabismus}, volume = {53}, year = {2016}, month = {2016 Nov 01}, pages = {339-343}, abstract = {

PURPOSE: To review the impact of vitrectomy and tube shunts on mean intraocular pressure (IOP) and number of glaucoma medications in pediatric aphakic glaucoma.

METHODS: A retrospective review of pediatric patients who underwent combined vitrectomy and glaucoma tube shunt surgery for aphakic glaucoma was conducted. Inclusion criteria were: age 18 years or younger, diagnosis of aphakic glaucoma, preoperative IOP data, and postoperative IOP data for at least 6 months. Mean IOP lowering at 1 year, number of glaucoma medications at 1 year, and surgical complications, including tube occlusion in the postoperative period, were noted.

RESULTS: The mean \± standard deviation preoperative IOP was 33.9 \± 10.6 mm Hg (range: 18 to 57 mm Hg) with a mean of three topical IOP-lowering medications. A total of 5 (36\%) Ahmed and 9 (64\%) Baerveldt tube shunts were placed. One of the Baerveldt tube shunt procedures was combined with revision of a traumatically dislocated tube. The mean IOP at 12 months postoperatively was 16.6 \± 5.8 mm Hg (range: 6 to 28 mm Hg; P \< .01, t = 3.74, df = 13) with a mean of 2.3 glaucoma medications. There were no cases of tube occlusion, corneal decompensation, endophthalmitis, or retinal detachment over the 12 months of follow-up.

CONCLUSIONS: Combined vitrectomy and placement of a glaucoma tube shunt can be safe and effective in lowering IOP based on mean IOP values and number of glaucoma medications at 1 year. [J Pediatr Ophthalmol Strabismus. 2016;53(6):339-343.].

}, keywords = {Adolescent, Aphakia, Postcataract, Cataract, Cataract Extraction, Child, Child, Preschool, Female, Glaucoma, Glaucoma Drainage Implants, Humans, Infant, Intraocular Pressure, Male, Retrospective Studies, Visual Acuity, Vitrectomy}, issn = {1938-2405}, doi = {10.3928/01913913-20160818-01}, author = {Elshatory, Yasser M and Gauger, Elizabeth H and Kwon, Young H and Alward, Wallace L M and Boldt, H Culver and Russell, Stephen R and Mahajan, Vinit B} } @article {113, title = {23-gauge pediatric vitrectomy using limbus-based trocar-cannulas.}, journal = {Retina (Philadelphia, Pa.)}, volume = {32}, year = {2012}, month = {2012 May}, pages = {1023-7}, keywords = {Catheters, Child, Child, Preschool, Female, Glaucoma Drainage Implants, Humans, Infant, Male, Microsurgery, Retinal Detachment, Retrospective Studies, Vitrectomy, Vitreous Hemorrhage}, author = {Kay, Christine N and Quiram, Polly H and Mahajan, Vinit B} } @article {157, title = {Collagen XVIII mutation in Knobloch syndrome with acute lymphoblastic leukemia.}, journal = {American journal of medical genetics. Part A}, volume = {152A}, year = {2010}, month = {2010 Nov}, pages = {2875-9}, abstract = {

Knobloch syndrome (KNO) is caused by mutations in the collagen XVIII gene (COL18A1) and patients develop encephalocele and vitreoretinal degeneration. Here, we report an El Salvadorian family where two sisters showed features of KNO. One of the siblings also developed acute lymphoblastic leukemia. DNA sequencing of COL18A1 revealed a homozygous, 2-bp deletion (c3514-3515delCT) in exon 41, which leads to abnormal collagen XVIII and deficiency of its proteolytic cleavage product endostatin. KNO patients with mutations in COL18A1 may be at risk for endostatin-related conditions including malignancy.

}, keywords = {Base Sequence, Child, Child, Preschool, Collagen Type XVIII, DNA Mutational Analysis, Encephalocele, Eye Abnormalities, Family, Female, Humans, Infant, Magnetic Resonance Imaging, Male, Molecular Sequence Data, Mutation, Pedigree, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Retinal Detachment}, author = {Mahajan, Vinit B and Olney, Ann Haskins and Garrett, Penny and Chary, Ajit and Dragan, Ecaterina and Lerner, Gary and Murray, Jeffrey and Bassuk, Alexander G} }